
Gilead Sciences (GILD) Stock Forecast & Price Target
Gilead Sciences (GILD) Analyst Ratings
Bulls say
Gilead Sciences demonstrates a positive outlook driven by robust sales growth, particularly highlighted by Biktarvy capturing 52% of the U.S. market share, reflecting an increase from 49% in the previous quarter. The company's proactive approach in the HIV market, along with rising awareness and education around PrEP, has led to an increased sales forecast, revising growth guidance to 5% year-over-year despite anticipated Medicare Part D challenges. Additionally, the strong performance of Livdelzi, which recorded $105 million in sales and a notable 35% quarter-over-quarter growth in its first full year, underscores the potential for continued success across Gilead's therapeutic portfolio.
Bears say
Gilead Sciences is experiencing significant revenue decline across multiple therapeutic areas, with notable drops in both Trodelvy and Veklury sales, indicating challenges in maintaining market share against competitors. The company has forecasted a roughly 10% decrease in cell therapy revenue for FY2025, reflecting ongoing competitive pressures that are anticipated to persist in the oncology market. Additionally, Veklury revenue is projected to fall to $1.0 billion for FY2025, a substantial reduction from previous guidance, further emphasizing the company's struggles in a declining demand environment.
This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.
Gilead Sciences (GILD) Analyst Forecast & Price Prediction
Start investing in Gilead Sciences (GILD)
Order type
Buy in
Order amount
Est. shares
0 shares